Is Takeda Pharmaceutical Company Limited (TAK) a Buy, Sell, or Hold?
Takeda Pharmaceutical Company Limited
NYSE:TAK
$16.39 USD
-$0.1 (-0.61%)
- Volume
- 5.06M
- Average Volume
- 2.95M
- Market Capitalization
- $52.14B
- P/E Ratio
- 43.35
- Dividend Yield
- 3.78%
- Price Target
- $
- Year High
- $18.90
- Year Low
- $12.99
- Day High
- —
- Day Low
- —
- Payout Ratio
- $1.63
- Current Ratio
- $1.27
Industry, Sector & symbol
| Stock Exchange | NYSE |
| CEO | Christophe Weber |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Current Symbol | TAK |
| CUSIP | 874060205 |
| CIK | 0001395064 |
| Web | https://www.takeda.com |
| Phone | 81 3 3278 2111 |
| Currency | USD |
| Employees | 47029 |
| Country | JP |
Liquidity
| Debt-to-Equity Ratio | 0.63 |
| Payout Ratio | 1.63 |
| Current Ratio | 1.27 |
| Quick Ratio | 0.70 |
| Cash Ratio | 0.24 |
Sales & Book Value
| Annual Sales | $4.78T |
| Price / Sales | 1.87 |
| Cash Flow | 500.69 |
| Price / Cash Flow | 10.75 |
| Price / Book | 1.06 |
Price Target and Rating
| Average Stock Price Forecast | $ |
| High Stock Price Forecast | $ |
| Low Stock Price Forecast | $ |
| Forecast Upside/Downside | % |
| Consensus Rating | Neutral |
| Rating Score(0-5) | 3 |
| Research Coverage | 6 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $63.91 |
| Trailing P/E Ratio | 43.35 |
| PEG Ratio | 0.56 |
| P/E Growth | 0.56 |
| Net Income | $203.33B |
| Net Margin | 4.26% |
| Pretax Margin | 5.77% |
| Return on Equity | 2.61% |
| Return on Assets | 1.24% |
Financials Score
| AltmanZ Score | 1.23 |
| Piotroski Score | 7.00 |
| Working Capital | 663.84B |
| Total Assets | 15.52T |
| Ebit | 622.25B |
| Market Cap | 8.46T |
| Total Liabilities | 7.71T |
Poll Results
About Takeda Pharmaceutical Company Limited (NYSE:TAK) Stock
Takeda Pharmaceutical Company Limited is a prominent global biopharmaceutical entity dedicated to the discovery, development, manufacturing, commercialization, and out-licensing of pharmaceutical products. The company's operations extend across a vast international footprint, encompassing Japan, the United States, Europe, Canada, Latin America, Russia, and numerous other Asian and worldwide markets. Its extensive portfolio of medicines targets critical therapeutic areas, including digestive disorders (gastroenterology), rare diseases, plasma-derived treatments, cancer care (oncology), and neurological conditions. Takeda markets these products under various well-recognized brand names, such as Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livt ... encity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig. To further its innovative endeavors, Takeda engages in a wide array of strategic partnerships. These include out-licensing arrangements, notably with Neurocrine Biosciences, Inc.; numerous collaboration and in-licensing agreements with institutions like the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., Ovid Therapeutics Inc., and Evox Therapeutics Ltd.; and a licensing deal with ProThera Biologics Inc. The company also fosters research collaborations and licensing agreements with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, Selecta Biosciences, BridGene Biosciences, Skyhawk Therapeutics, and StrideBio. Furthermore, it maintains strategic alliances with Egle Therapeutics SAS, Evotec SE, Neurocrine Biosciences, Inc., Carmine Therapeutics, KSQ Therapeutics, and Anima Biotech. Founded in 1781, Takeda Pharmaceutical Company Limited is headquartered in Tokyo, Japan.
2026-07-12 19:00:00
OSAKA, Japan & CAMBRIDGE, Mass. & JAKARTA, Indonesia--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) and the Indonesian Government (the Ministry of Health, the Ministry of Investment and Downstream Industry/BKPM and the Coordinating Ministry for Economic Affairs) today announced a groundbreaking collaboration aimed at strengthening Indonesia's plasma ecosystem and supporting more equitable access to lifesaving plasma-derived medicinal products (PDMPs) in Indonesia and around the world. Marked by a.
Insilico Medicine Announces Collaboration with Takeda to Advance Strategic AI Drug Discovery
2026-07-01 22:16:00
Partnership to leverage Pharma.AI platform for novel drug candidates across Takeda's therapeutic areas CAMBRIDGE, Mass., July 1, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico" HKEX:3696), a leader in clinical-stage generative AI for drug discovery, today announced a strategic collaboration agreement with Takeda to use its proprietary end-to-end platform, Pharma.AI, to advance drug candidates across the company's therapeutic areas.
Takeda, InSilico Strike AI Drug-Discovery Deal Worth Up to $600 Million
2026-07-01 19:59:00
Takeda is set to pay InSilico to use its proprietary Pharma. AI platform to advance drug candidates across several therapeutic areas, according to people familiar with the matter.
Recursion Pharmaceuticals vs. Summit Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
2026-06-30 07:45:03
Recursion harnesses AI for large-scale drug discovery, while Summit's betting on a single oncology candidate. How do their financials and risk profiles stack up?
2026-06-24 03:05:00
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--In the final step of its 18-month CEO transition, Takeda (TOKYO:4502/NYSE:TAK) today announced that Julie Kim was officially appointed Takeda's Representative Director, President and Chief Executive Officer. During the 150th Annual General Meeting of Shareholders, which took place in Osaka, Japan, shareholders elected Julie as a new internal director to the Board of Directors. Following the vote and conclusion of the meeting, the Board of Direct.
2026-06-15 12:00:00
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today presented additional results from two pivotal studies at SLEEP 2026, showing oveporexton (TAK-861), an oral orexin receptor 2 (OX2R)-selective agonist, improved daily functioning as well as cognitive and sleep-related symptoms associated with narcolepsy type 1 (NT1).1,2,3 Oveporexton is designed to address the underlying orexin deficiency that causes NT1 by restoring orexin signaling. These data, along with previ.
Takeda's AI-crafted psoriasis pill tops Bristol Myers' Sotyktu in head-to-head trial
2026-06-11 07:03:31
Japan's Takeda Pharmaceutical said on Thursday its experimental once-daily psoriasis pill, developed with the help of AI, outperformed Bristol Myers Squibb's approved drug Sotyktu in a late-stage head-to-head study.
2026-06-11 07:00:00
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) announced positive topline results for the Phase 3, randomized, multicenter, double-blind study comparing zasocitinib (TAK-279), an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, to deucravacitinib in adults with moderate-to-severe plaque psoriasis (PsO). In the LATITUDE Atlas (TAK-279-PsO-3004) head-to-head study, zasocitinib demonstrated statistical superiority.
Frequently Asked Questions
-
What is the current Takeda Pharmaceutical Company Limited (TAK) stock price?
-
Takeda Pharmaceutical Company Limited(NYSE:TAK) stock price is $16.39 in the last trading session. During the trading session, TAK stock reached the peak price of $18.9 while $12.99 was the lowest point it dropped to. The percentage change in TAK stock occurred in the recent session was --0.61% while the dollar amount for the price change in TAK stock was -$-0.1.
-
TAK's industry and sector of operation?
-
The NYSE listed TAK is part of Drug Manufacturers - Specialty & Generic industry that operates in the broader Healthcare sector.
-
Who are the executives of TAK?
-
So-Young Kim | CEO, President & Director
Norimasa Takeda | Chief Accounting Officer & Corporate Controller
Christopher J. Morabito | Head of R&D Pipeline Strategy
Christopher David O'Reilly | Global Head of Investor Relations & Global Finance
Giles Platford | President of International Business Unit -
How many employees does TAK have?
-
Number of TAK employees currently stands at 47029. TAK operates from 1-1, Nihonbashi-Honcho 2-chome, Tokyo, None 103-8668, JP.
-
Link for TAK official website?
-
Official Website of TAK is: https://www.takeda.com
-
How do I contact TAK?
-
TAK could be contacted at phone #81 3 3278 2111 and can also be accessed through its website. TAK operates from 1-1, Nihonbashi-Honcho 2-chome, Tokyo, None 103-8668, JP.
-
How many shares of TAK are traded daily?
-
The average number of TAK shares traded daily for last 3 months was 2.95M.
-
What is the market cap of TAK currently?
-
The market value of TAK currently stands at $52.14B with its latest stock price at $16.39